Current problems with tuberculosis treatment.
Grosset
J
J
Laboratoire Central de Bactériologie-Virologie et Hygiène, Groupe Hospitalier Pitié-Salpêtrière, Paris.
D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D010131:Aminosalicylic Acid / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D006801:Humans; D015994:Incidence; D007538:Isoniazid / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use; D012959:Socioeconomic Factors; D013307:Streptomycin / Q000627:therapeutic use*; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*
D000904:Antibiotics, Antitubercular; D000995:Antitubercular Agents; D010131:Aminosalicylic Acid; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin